ArticleEJNMMI research2026
Development and evaluation of the first-in-class nanobody based PET tracer targeting human inducible T-cell co-stimulator receptor.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInducible T-cell co-stimulator receptor (ICOS) is a conserved biomarker mainly expressed on activated T cells. It had been proved that PET imaging targeting ICOS was a promising strategy for assessment of immune responses in cancer immunotherapy. For further translating this strategy into clinic, in the present study, we had developed the first-in-class ICOS targeting nanobody ICOS-53 via alpaca immunization and yeast display screening.
resultsThe binding affinity of ICOS-53 to recombinant ICOS protein was validated by surface plasmon resonance, and the KD value was 85.3 pM. ICOS-53 was then conjugated to NOTA and radiolabeled with [68Ga]GaCl3. In PET imaging study, higher accumulation of [68Ga]Ga-NOTA-ICOS-53 could be observed in CHO-ICOS (CHO transfected by human ICOS) tumors, compared to CHO (Chinese Hamster Ovary cells) cohort from all-time points examined. Statistically significant correlation between PET imaging quantitative results and biodistribution could be observed (R = 0.548, P = 0.00117). Immunofluorescence staining also confirmed the high ICOS expression in CHO-ICOS tumors.
conclusionOur data demonstrated that we had developed a novel nanobody based PET tracer targeting human ICOS, [68Ga]Ga-NOTA-ICOS-53 PET imaging was a promising strategy for tracking ICOS+ cells both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.